Inhibitory Effect of Bee Venom Herbal Acupuncture Solution on Acetylcholinesterase in PC 12 Cells

국문 초록 (Abstract)

목적 : Acetylcholine은 콜린과 아세트산의 에스테르로 인체에서 중요한 신경전달물질로 Acetylcholine- sterase(AChE)라는 효소에 의해 분해된다. Alzheimer’s disease, ataxia, myasthenia gravis, Parkinson’s disease 등의 질환에 AChE 억제제가 사용되어 왔으며 최근 한약재의 AChE 억제 효능에 관한 연구들도 진행되고 있다.
봉독은 관절염, 통풍 등의 질환에 응용되어 왔으며 진통효과 및 항염증작용에 대한 임상적, 실험적 연구가 많이 보고되어 왔으나 AChE 억제효과에 대한 연구는 아직까지 보고된 바 없다. 본 연구에서는 봉독약침액과 봉독의 과민반응 유발항원 중 하나인 Phospholipase A2 억제효능이 있는 것으로 알려진 상백피를 혼합한 상백피봉독약침액의 AChE 억제효과를 알아보았다.
방법 : PC12 세포주에서 추출한 AChE와 0.1, 0.01 and 0.001㎎/㎖ 농도의 봉독약침액 및 상백피봉독약침액을 60분간 반응시켰다. 효소면역측정법(ELISA)을 이용하여 흡광도를 10분, 30분, 60분 경과시 각각 측정한 후 효소활성저해도(%)를 계산하였다.
효소활성저해도(%) = [(Cc–Ce)/Cc]×100
Cc : 대조군 흡광도, Ce : 실험군 흡광도
결과 :
1. 봉독약침액은 0.1, 0.01, 0.001㎖/㎎의 농도에서 30분 경과 후부터 유의성 있는 억제효과를 나타내었다.
2. 상백피봉독약침액은 0.1㎖/㎎ 농도에서 10분 경과 후부터 유의성 있는 억제효과를 나타내었고, 0.01㎖/㎎ 농도에서 30분경과 시 유의성 있는 억제효과를 나타내었다.
3. 봉독약침액과 상백피봉독약침액의 AChE 억제효과 비교에서 봉독약침액의 억제효과가 상백피봉독약침액보다 뛰어났다.
요약 : 봉독약침액과 상백피봉독약침액의 AChE 억제효과를 확인하여 두 군 모두 유의성 있는 결과를 얻을 수 있었다. 앞으로 알츠하이머병이나 치매와 같은 신경퇴행성 질환에 대한 봉독의 임상적 활용 및 보다 넓은 범위에 대한 연구가 필요할 것이라 사료된다.

참고문헌 (Reference)

1 Viegas CJ, 5 : 915-926, 2005

2 Yin CS, "The first documental record on bee venom therapy in Oriental medicine : 2 prescriptions of bee venom in the ancient Ma- wangdui books of Oriental medicine" 15 (15): 143-147, 1998

3 Rieger F, "The effects of nerve growth factor on acetylcholinesterase and its multiple forms in cultures of rat PC12 pheo- chromocytoma cells : increased total specific ac- tivity and appearance of the 16 S molecular form" 76 (76): 238-243, 1980

4 Kwon GR, "The clinical studies to de- veloping BV partner" 4 (4): 93-99, 2001

5 Kasa P, "The cholinergic system in Alzheimer’s disease" 52 : 511-535, 1997

6 Bartus RT, "The cholinergic hypothesis of geriatric memory dysfunction" 217 (217): 408-414, 1982

7 Davies P, "Selective loss of central cholinergic neurons in Alzheimer’s disease" 8000 (8000): 1403-, 1976

8 Davies P, "Selective loss of central cholinergic neurons in Alzheimer’s disease" 2 : 1403-, 1976

9 Brlihlmann C, "Screening of non-alkaloidal natural compounds as acetylcholinesterase inhibitors" 1 : 819-829, 2004

10 Oh MH, "Screening of Korean herbal medicines used to improve cognitive function for anti-cholinestera- se activity" 11 : 544-548, 2004

11 Gottwald MD, "Rivastigmine a brain- region selective acetylcholinesterase inhibitor for treating Alzheimer’s disease : review and cur- rent status" 8 : 1673-1682, 1999

12 Sims NR, "Presynaptic cholinergic dysfunc- tion in patients with dementia" 40 : 503-509, 1983

13 Brenner GM., "Pharmacology" Philadelphia : WB. Saunders Company 2000

14 Price DL., "New perspectives on Alzheimer’s di- sease" 9 : 489-512, 1986

15 Melzer D, "New drug treatment for Alzheimer’s diseases : lessons for healthcare policy" 316 : 762-764, 1998

16 Mortensen SR, "Maturational differences in chlorpyrifos-oxo- nase activity may contribute to age-related sen- sitivity to chlorpyrifos" 11 (11): 279-287, 1996

17 Giacobini E., "Long term stabilizing effect of cho- linesterase inhibitors in the therapy of Alzheimer’s disease" 181-187, 2002

18 Camps P, "Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treat- ment of Alzheimer’s disease" 57 (57): 409-417, 2000

19 Ingkaninan K, "High-performance liquid chromatogra- phy with on-line coupled UV, mass spectrome- tric and biochemical detection for identification of acetylcholinesterase inhibitors from natural pro- ducts" 872 : 61-73, 2000

20 Schulz V., "Ginkgo extract or cholinesterase inhi- bitors in patients with dementia : what clinical trial and guidelines fail to consider" 10 : 74-79, 2003

21 Scott LJ, "Galantamine : a review of its use in Alzheimer’s disease" 60 : 1095-1122, 2000

22 Muramoto O, "Effect of physostigmine on constructional and memory tasks in Alzheimer’s disease" 36 (36): 501-503, 1979

23 Kelly CA, "Drug treatments for Alzheimer’s disease" 314 : 693-694, 1997

24 Andrisano V, "Determination of inhibitors’ potency(IC50) by a direct high performance liquid chromato- graphic method on an immobilized acetylcholine- sterase column" 753 : 375-383, 2001

25 DeKosky ST, "Cortical biopsy in Alzheimer’s disease : diagnostic accuracy and neu- rochemical, neuropathological and cognitive cor- relations" 32 : 625-632, 1992

26 Anonymous, "Compendium of Pharmaceuticals and Specialties" Toronto. Canada : Canadian Pharmacists Association 2000

27 Birks J., "Cochrane Database Syst" 25 : CD005593-, 2006

28 Whitehouse PJ., "Cholinergic therapy in dementia" 149 : 42-45, 1993

29 Habermann E., "Chemistry, pharmacology and to- xicology of bee, wasp and hornet venoms" Acade- mic Press 3 : 61-, 1971

30 Barbara R., "Chemistry and pharmacology of ho- ney bee venom" Academic Press 329-402, 1986

31 Rahman AU, "Bioactive natural products as a potential source of new pharma- cophores a theory of memory" 73 : 555-560, 2001

32 Lee JH, "Bee venom pre- treatment has both an antinociceptive and anti- inflammatory effect on carrageenan-induced in- flammation" 63 (63): 251-259, 2001

33 Heppner FL, "Alzheimer Dis Assoc" 18 : 38-43, 2004

34 Marston A, "A rapid TLC bioautographic method for the detection of acetylcholinesterase and butyrylcholinesterase in- hibitors in plants" 13 : 51-54, 2002

35 Ellman GL, "A new and rapid colorimetic deter- mination of acetylcholinesterase activity" 7 : 88-95, 1961